Trial reportPrecision clinical medicine2024
Double-blinded, randomized clinical trial of Gegen Qinlian decoction pinpoints
Trial report in Precision clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 3 syntheses or guidelines pooled it, 18 citations in OpenAlex.
- Efficacy of Gegen Qinlian decoction plus metformin for type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.Frontiers in endocrinology · 2026 · on this mapPooled it
- The effects of Gegen Qinlian decoction and its main constituents on glucolipid metabolic disorders in diabetes: an overview of systematic reviews and meta-analysis.Systematic reviews · 2025Pooled it
- Efficacy and safety of Chinese herbal medicine for metabolic conditions: a systematic review and meta-analysis of randomised controlled trials.Frontiers in pharmacology · 2025Pooled it
- Randomized controlled clinical trial of Shenzhuo Formula in the treatment of macroalbuminuria in diabetic kidney disease and its inflammation-modulating mechanisms.Precision clinical medicine · 2025Trial
- The Clinical Efficacy of Gegen Qinlian Decoction in Treating Type 2 Diabetes is Positively Correlated with the Dose ofDrug design, development and therapy · 2024Trial
- An innovative model for integrated traditional Chinese and Western medicine: state-target differentiation and treatment.Science China. Life sciences · 2026Review
- Global Probiotic Markets Meet Synthetic Biology: Translational Challenges andMicroorganisms · 2026Review
- Beneficial Effects of Gegen Qinlian Decoction and Its Food-Medicine Homologous Alternative Formulas Against Type 2 Diabetes Mellitus: Insights from Multi-Omics Analysis.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Review
- Microbiota-metabolites interaction associated with glycemic improvement following a dietary herbal intervention in type 2 diabetes.Frontiers in nutrition · 2026Article
- Research on the characteristics of gut microbiota in overweight patients with early-onset type 2 diabetes mellitus.Journal of diabetes investigation · 2025Article
- Comparative diabetes mellitus burden trends across global, Chinese, US, and Indian populations using GBD 2021 database.Scientific reports · 2025Article
- Gut microbiota and its metabolites regulate insulin resistance: traditional Chinese medicine insights for T2DM.Frontiers in microbiology · 2025Review
- Response to Professor Hu Jinyu's Letter [Response to Letter].Drug design, development and therapy · 2025Article
- Modulating the Gut Microbiota and Metabolites with Traditional Chinese Medicines: An Emerging Therapy for Type 2 Diabetes Mellitus and Its Complications.Molecules (Basel, Switzerland) · 2024Review
- Global research trends in regulating gut microbiome to improve type 2 diabetes mellitus: bibliometrics and visual analysis.Frontiers in endocrinology · 2024Review
- Effect of Gegen Qinlian Decoction on the regulation of gut microbiota and metabolites in type II diabetic rats.Frontiers in microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 9 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Accumulating evidence suggests that metabolic disorders, including type 2 diabetes mellitus (T2DM), can be treated with traditional Chinese medicine formulas, such as the Gegen Qinlian decoction (GQD). This study elucidates the mechanisms by which gut microbes mediate the anti-diabetic effects of GQD. Methods: We conducted a double-blind randomized clinical trial involving 120 untreated participants with T2DM. During the 12-week intervention, anthropometric measurements and diabetic traits were recorded every 4 weeks. Fecal microbiota and serum metabolites were measured before and after the intervention using 16S rDNA sequencing, liquid chromatography-mass spectrometry, and Bio-Plex panels. Results: Anti-diabetic effects were observed in the GQD group in the human trial. Specifically, glycated hemoglobin, fasting plasma glucose, and two-hour postprandial blood glucose levels were significantly lower in the GQD group than in the placebo group. Additionally, Conclusions: GQD improved type 2 diabetes primarily by modulating the abundance of Trial registration: Registry No. ChiCTR-IOR-15006626.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.